TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

TMPRSS2–ERG gene rearrangement is seen in about half of clinically localized prostate cancers, yet controversy exists with regard to its prognostic implications. Similarly, the relationship of TMPRSS2–ERG fusion to Gleason score and morphology remains uncertain. We assigned Gleason scores and recorded morphological features for 521 clinically localized prostate cancers sampled in triplicate and arrayed in eight tissue microarray blocks. Fluorescence in situ hybridization was performed to delineate TMPRSS2–ERG aberrations. Using maximum Gleason score, based on three core evaluation, and overall Gleason score, based on prostatectomy sections, Fisher's exact test was performed for tumors with TMPRSS2–ERG translocation/deletion, copy number increase (≥3) of the TMPRSS2–ERG region without translocation/deletion, and copy number increase and concomitant translocation/deletion. In all, 217 (42%) translocation/deletion and 30 (5.9%) copy number increase-alone cases were detected. Among 217 translocation/deletion cases, 32 had translocation/deletion with copy number increase. In all, 237, 200, and 75 cancers had maximum core-specific Gleason score of 6, 7, and 8–10, respectively. Tumors with translocation/deletion tended toward lower Gleason scores than those without (P=0.002) with similar results for overall Gleason score (P=0.02); copy number increase cases tended toward higher Gleason scores than those without (P<0.001). Gleason score of 8–10 tumors demonstrated lower odds of translocation/deletion (odds ratio (OR) 0.38; 95% CI 0.21–0.68) and higher odds of copy number increase alone (OR 7.33; 95% CI 2.65–20.31) or copy number increase+translocation/deletion (OR 3.03; 95% CI 1.12–8.15) relative to Gleason score of <7 tumors. No significant difference in TMPRSS2–ERG incidence was observed between patients with and without cribriform glands, glomerulations, signet-ring cells, or intraductal cancer (P=0.821, 0.095, 0.132, 0.375). TMPRSS2–ERG gene fusion is associated with lower core-specific and overall Gleason scores and not with high-grade morphologies. Conversely, TMPRSS2–ERG copy number increase, with or without rearrangement, is associated with higher Gleason score. These findings indicate that translocation/deletion of TMPRSS2–ERG is not associated with histological features of aggressive prostate cancer.

[1]  Daniel S. Miller,et al.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[2]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[3]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[4]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[5]  R. Dhir Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy , 2010 .

[6]  J. Epstein Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy , 2004, Modern Pathology.

[7]  Adam S. Kibel,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007 .

[8]  P. Humphrey,et al.  Diagnosis of adenocarcinoma in prostate needle biopsy tissue , 2007, Journal of Clinical Pathology.

[9]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[10]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[11]  Sten Nilsson,et al.  Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens , 2005, Scandinavian journal of urology and nephrology. Supplementum.

[12]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[13]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[14]  E. Platz,et al.  TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas , 2009, Modern Pathology.

[15]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[16]  M. Cooperberg,et al.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. , 2005, The Journal of urology.

[17]  U. Ferreira,et al.  Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. , 2008, International braz j urol : official journal of the Brazilian Society of Urology.

[18]  W. Isaacs,et al.  TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.

[19]  J. Epstein,et al.  Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance , 2006, Modern Pathology.

[20]  J. Epstein,et al.  Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. , 1999, The American journal of surgical pathology.

[21]  S. Leung,et al.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.

[22]  H. Scher Management of prostate cancer after prostatectomy: treating the patient, not the PSA. , 1999, JAMA.

[23]  Yao-Tseng Chen,et al.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.

[24]  Ximing J. Yang,et al.  Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy: An Interobserver Study among Experts in Genitourinary Pathology , 2008, The American journal of surgical pathology.

[25]  M. Leversha Mapping of genomic clones by fluorescence in situ hybridization. , 2001, Methods in molecular biology.

[26]  D. Gleason,et al.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. , 1974, The Journal of urology.

[27]  R. Shah,et al.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.

[28]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[29]  J. McNeal,et al.  Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. , 1996, The American journal of surgical pathology.

[30]  M. Rubin,et al.  Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.

[31]  R. Shah,et al.  Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma , 2009, Modern Pathology.

[32]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[33]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[34]  D. Bostwick,et al.  Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. , 2009, Archives of pathology & laboratory medicine.

[35]  C. LaFargue,et al.  TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort , 2009, Cancer biology & therapy.

[36]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[37]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .

[38]  Myron Tanncnbaum,et al.  Urologic pathology: The prostate , 1977 .

[39]  Arul M Chinnaiyan,et al.  Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.

[40]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[41]  J. Brooks,et al.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.

[42]  J. Trachtenberg,et al.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.

[43]  J. Epstein,et al.  Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy: A Study of 47 Cases , 2008, The American journal of surgical pathology.

[44]  Murali Varma,et al.  Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. , 2002, Archives of pathology & laboratory medicine.

[45]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M E Hammond,et al.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.